Gene

ETV5

ETS variant transcription factor 5

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ETV5 Overexpression2
Trametinib	Malignant Pancreatic Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID5120 In vitro studies in KRAS G12V pancreatic cancer cells (PATU8902) showed that overexpression of ETV5 reduced sensitivity to trametinib. PMID 28178529 · Wang et al., 2017 · Open in CIViC	civic
〃	Malignant Lung Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID5122 In vitro studies in KRAS G12C lung cancer cells (CALU1) showed that overexpression of ETV5 modulated resistance to trametinib. PMID 28178529 · Wang et al., 2017 · Open in CIViC	civic

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved8 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Lung Squamous Cell Carcinoma TCGA-LUSC	Lung Squamous Cell Carcinoma	Ssm

Literature

Data not yet available

No publication linked to this gene yet.